What resin substitution range forces Boc-β-alanine stoichiometry above 2 molar equivalents in Fmoc-SPPS?

Boc-β-alanine (CAS 3303-84-2) enters solid-phase peptide synthesis as a protected β-amino acid whose free carboxyl group is activated in situ. In automated Fmoc-SPPS trains operating with 2-chlorotrityl chloride resin at loading values between 0.3 mmol/g and 0.8 mmol/g, coupling efficiency for this non-proteinogenic building block becomes unreliable when the equivalent ratio is reduced below 2.0 relative to free amino functions. The standard activation recipe therefore uses 2.0–4.0 mol eq of Boc-β-alanine, 2.0–4.0 mol eq of HOBt or OxymaPure, and 2.0–4.0 mol eq of DIC in DMF or NMP at 20–25 °C for 18–30 min. Resins with substitution above 1.0 mmol/g reduce site accessibility and require the lower equivalence limit to be raised or double coupling to be applied. Process monitoring is carried out with ninhydrin or chloranil tests; a positive re-test following the first coupling triggers a re-coupling cycle using 1.5 mol eq of the same activated species. Deprotection of Fmoc groups uses 20% v/v piperidine in DMF, while final side-chain deprotection and cleavage employ TFA/triisopropylsilane/water at 95:2.5:2.5 v/v/v for 2–4 h. Compliance for peptide APIs manufactured from Boc-β-alanine is anchored to ICH Q7, with starting-material controls assessed under ICH Q11 and residual solvent limits applied according to ICH Q3C Table 2. Terminal product classes include generic peptide APIs, custom peptide drug substances, and peptide fragments for longer sequences containing β-alanine residues; the protected monomer itself is not released as a formulation component. A practical bottleneck on production-scale automated synthesizers occurs when high-loading resins generate exotherms during rapid carboxylate activation with HATU/DIPEA; jacket-controlled reaction vessels maintaining 18–22 °C suppress by-product formation and preserve crude purity above 85% in typical 10–20-mer peptide sequences. The absence of a side chain on β-alanine permits high solvent exposure during coupling but increases susceptibility to side reactions under prolonged strong base; piperidine exposure is therefore strictly limited to 2 × 5 min cycles for sequences containing this residue.

In solution-phase manufacture of protected dipeptide intermediates, Boc-β-alanine is used predominantly as an acid component in carbodiimide-mediated amide bond formation. The charge ratio is maintained at 1.05–1.20 mol eq of Boc-β-alanine per equivalent of amine-bearing amino acid ester, with EDC·HCl at 1.1–1.3 mol eq, HOBt or HOAt at 1.0 mol eq, and N-methylmorpholine at 2.0 mol eq in dichloromethane or tetrahydrofuran. The reaction profile is initiated at 0–5 °C and allowed to warm to 20–25 °C over 12–18 h. Aqueous work-up with 5% m/v citric acid and 5% m/v sodium bicarbonate removes urea by-products before solvent exchange into ethyl acetate for crystallization. The N-Boc group remains intact during this stage and is later removed using 4 M hydrogen chloride in 1,4-dioxane or 30–50% v/v TFA in dichloromethane. Compliance for this route is set by ICH Q7 and ICH Q11 in early-phase cGMP manufacturing, with ICH Q3C Table 2 governing dichloromethane as a Class 2 solvent and ICH Q3D governing elemental impurities introduced through metal-based coupling reagents. End products are protected dipeptide fragments such as N-Boc-β-alanyl-amino acid tert-butyl esters, which are subsequently advanced to API intermediates for oral small molecules and enzyme inhibitor programs. Residual trifluoroacetyl or chloride salts after deprotection are controlled by ion chromatography and HPLC purity determination before downstream coupling. This route is generally limited to solution-phase campaigns where the target sequence is short; isolation of the free β-alanyl intermediate is avoided when it exhibits low stability under prolonged storage at ambient humidity.

Active ester activation and orthogonally protected linker assembly for bioconjugation intermediates

Boc-β-alanine is converted into its N-hydroxysuccinimide ester for insertion of a β-alanine spacer into heterobifunctional linkers used in antibody–drug conjugate and radiopharmaceutical synthesis. The activation reaction is conducted with 1.0 mol eq Boc-β-alanine, 1.05 mol eq N-hydroxysuccinimide, and 1.05 mol eq dicyclohexylcarbodiimide in anhydrous 1,4-dioxane or DMF at 0–5 °C for 6–12 h. The resulting dicyclohexylurea precipitate is removed by filtration through a 0.45 μm PTFE membrane. The activated Boc-β-alanine NHS ester is then coupled to amino-terminated polyethylene glycol or aliphatic linker arms at 1.0–1.3 mol eq relative to the free amine. This two-step sequence preserves the Boc protecting group until the final acidolytic deprotection step, allowing subsequent maleimide or azide introduction without spurious polymerization. Compliance in this application is defined by ICH M7 with a threshold of toxicological concern of 1.5 μg/day for mutagenic impurity risk assessment of activated ester intermediates, ICH Q3D for elemental impurities from carbodiimide reagents, and ICH Q7 for manufacturing controls when the linker is allocated to a registered drug substance intermediate. Terminal product classes include β-alanine-containing PEG spacers, NHS ester functional intermediates, and maleimide–PEG–β-alanine acid constructs intended for conjugating cytotoxic payloads or chelators. The operational boundary is moisture: hydrolysis of the NHS ester becomes measurable above 40% relative humidity, so handling is limited to nitrogen-purged gloveboxes or anhydrous solvent lines. In preparative campaigns with 10–50 L reactor volumes, DCU filtration can become rate-limiting; jacketed filter funnels with 5–10 μm retention filters are specified to prevent recrystallized DCU from contaminating the subsequent coupling step.

Cosmetic peptide contract development organizations consume Boc-β-alanine as a protected β-amino acid building block for short-chain biomimetic peptides in which a flexible β-alanine spacer is inserted between a lipophilic anchor and a peptide sequence. The manufacturing process follows Fmoc-SPPS on Rink amide resin at 0.6–1.0 mmol/g loading. Coupling is performed with 2.0–3.0 mol eq Boc-β-alanine, 2.0–3.0 mol eq HCTU, and 4.0–6.0 mol eq DIPEA in DMF at 25–30 °C for 20–40 min. The N-terminal Boc group is removed at the final TFA cleavage step to reveal the free amino terminus before lyophilization. Regulatory anchor points include ISO 22716:2007 for cosmetic good manufacturing practices in the peptide manufacturing suite, EC No 1223/2009 for final cosmetic product safety in the European Union, and ISO 9001:2015 for contract manufacturing quality systems. The finished output consists primarily of lyophilized cosmetic peptide ingredients and peptide conjugates supplied to skincare formulators; the Boc-protected intermediate does not enter the final cosmetic formula. Analytical release testing of the peptide lyophilizate includes reverse-phase HPLC purity, residual TFA by ion chromatography, and peptide content by amino acid analysis. This use is limited to research and development or pre-commercial formulation support where the final peptide supplier has established dermal safety documentation; Boc-β-alanine itself is not intended for direct cosmetic inclusion and has no cosmetic INCI function.

When fragment libraries demand β-amino acid acid coupling without residual carbodiimide contamination

Hit-to-lead and fragment synthesis groups deploy Boc-β-alanine in parallel amide coupling arrays to generate β-peptidomimetic compound libraries. The recommended stoichiometry for 10 μmol reaction scale is 1.2 mol eq Boc-β-alanine, 1.5 mol eq HATU or COMU, and 3.0 mol eq DIPEA in anhydrous DMF, with activation time 3–5 min at 20 °C followed by amine addition and 2–6 h reaction. Compliance for these early-phase screening compounds is less defined by GMP than by OECD GLP and ICH M7 control strategies when the library feeds into lead optimization for drug discovery; residual solvents remain monitored through ICH Q3C Table 1 and Table 2 if compounds are advanced to formal safety assessment. Downstream processes include automated liquid handling for solid-phase extraction, preparative LCMS fractionation, and lyophilization of screening samples in 96-well format. Terminal products are not commercial pharmaceuticals but N-Boc-protected β-peptidomimetic screening compounds, active protease inhibitor candidates, and solid support-bound ligand libraries. In parallel synthesis, the largest process failure is incomplete neutralization of excess HATU-derived by-products; the use of resin-bound scavengers such as aminomethyl polystyrene reduces carbodiimide-related impurities below 5% by LCMS area. Boc-β-alanine offers a distinct advantage in this setting because its Boc protecting group survives the basic coupling environment and collapses under TFA to generate a primary amine that can be selectively derivatized in subsequent library steps.

Mixed anhydride coupling of Boc-β-alanine to L-histidine methyl ester yields an isolable N-Boc-carnosine intermediate

Boc-β-alanine is a preferred protected β-amino acid in the solution-phase route to carnosine and zinc carnosine. The mixed anhydride method charges Boc-β-alanine at 1.0 mol eq relative to L-histidine methyl ester, with ethyl chloroformate at 1.0–1.05 mol eq and N-methylmorpholine at 1.1 mol eq in anhydrous tetrahydrofuran at −15 to −10 °C. The activated anhydride is formed over 20–40 min before the amine component is added, and the coupling mixture is allowed to warm to 20 °C over 6–12 h. The protected intermediate is isolated by aqueous work-up and crystallization before the Boc group is removed with 4 M hydrogen chloride in dioxane, yielding carnosine hydrochloride or the corresponding salt for downstream zinc carnosine manufacture. Compliance for this application is anchored to FDA 21 CFR Part 111 when the output is allocated to dietary supplement manufacturing, with residual solvent and heavy metal release criteria aligned to ICH Q3C and ICH Q3D principles. Terminal product classes include β-alanyl-L-histidine, carnosine hydrochloride, and zinc carnosine dietary supplement ingredients. In this route, incomplete removal of ethyl chloroformate-derived carbamates is controlled by treating the reaction stream with dilute bicarbonate, and residual ethyl chloroformate is monitored by headspace GC before deprotection; residual Boc-protected product must remain below 0.1% w/w by HPLC in the final dietary ingredient to avoid releasing tert-butanol and carbon dioxide decomposition artefacts into finished supplement formulations.